Karyopharm Therapeutics (NASDAQ:KPTI) Issues Quarterly Earnings Results

Posted by Geri Gentry on May 15th, 2026

Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($1.24) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.21, FiscalAI reports. The company had revenue of $35.07 million for the quarter, compared to analyst estimates of $31.40 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

Karyopharm said its phase III SENTRY trial in myelofibrosis met the main spleen response endpoint, with SVR35 at week 24 of 50% versus 28% for ruxolitinib alone and no new safety signals.
The company highlighted an encouraging overall survival signal in SENTRY, along with early variant allele frequency reductions that it believes may suggest disease-modifying activity.
XPORT-EC-042 in endometrial cancer has completed enrollment, and Karyopharm still expects top-line data in mid-2026 for the biomarker-driven maintenance study.
Management argued that its endometrial cancer program targets a large subgroup of TP53 wild-type, MMR-proficient patients and emphasized that the 60 mg weekly selinexor dose with mandated antiemetics should improve tolerability versus earlier studies.
First-quarter revenue rose to $35.1 million from $30.0 million a year ago, but management said underlying XPOVIO demand fell versus last year due to new competition; it reaffirmed full-year 2026 revenue and expense guidance and said liquidity should last into late Q3 2026.

Karyopharm Therapeutics Trading Up 0.6%

Shares of Karyopharm Therapeutics stock opened at $8.90 on Friday. The company has a market cap of $200.70 million, a price-to-earnings ratio of -0.54 and a beta of 0.80. Karyopharm Therapeutics has a 1 year low of $3.65 and a 1 year high of $10.99. The company’s fifty day simple moving average is $7.91 and its 200-day simple moving average is $7.26.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on KPTI shares. Piper Sandler restated an “overweight” rating and issued a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a research note on Monday, April 27th. Cantor Fitzgerald started coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating on the stock. Robert W. Baird lowered their price objective on shares of Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 25th. HC Wainwright raised their price objective on shares of Karyopharm Therapeutics from $8.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Rodman & Renshaw upgraded shares of Karyopharm Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.17.

View Our Latest Research Report on KPTI

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KPTI. XTX Topco Ltd bought a new position in Karyopharm Therapeutics in the second quarter worth $56,000. Baird Financial Group Inc. bought a new position in Karyopharm Therapeutics in the second quarter worth $45,000. Bank of America Corp DE lifted its position in Karyopharm Therapeutics by 26.8% in the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares during the period. Bridgeway Capital Management LLC bought a new position in Karyopharm Therapeutics in the second quarter worth $163,000. Finally, ADAR1 Capital Management LLC bought a new position in Karyopharm Therapeutics in the third quarter worth $164,000. 66.44% of the stock is owned by institutional investors.

About Karyopharm Therapeutics

(Get Free Report)

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.